Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Atrium Therapeutics Inc's Business Segments
Atrium Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 3
Regions Reported
-
Atrium Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Cardiology Indication76.4%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Cardiology Indication | $ 15 | 76.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Atrium Therapeutics Inc
Avidity Biosciences Inc is a biotechnology company that specializes in developing precision medicines using its proprietary technology called Antibody Oligonucleotide Conjugates (AOCs). The company was founded in 2012 and is headquartered in La Jolla, California.
Avidity Biosciences seeks to address the limitations of traditional antibody therapeutics by combining the targeting capabilities of antibodies with the precision and versatility of oligonucleotide-based therapies. AOCs are designed to specifically target cells and deliver therapeutic oligonucleotides directly into the cytoplasm of the cells.
The company's platform technology enables the development of novel therapies for a wide range of diseases, including cancer, autoimmune disorders, and rare genetic diseases. AOCs have the potential to target previously undruggable proteins and improve the efficacy and safety of existing therapies.
Avidity Biosciences has a strong focus on research and development to advance its pipeline of AOC-based drug candidates. The company collaborates with various academic institutions, industry partners, and research organizations to leverage their expertise and resources.
One of the notable achievements of Avidity Biosciences is its partnership with Eli Lilly and Company, a global pharmaceutical company. The collaboration aims to discover, develop, and commercialize new AOC-based therapies for immunology and other indications. This collaboration provides Avidity Biosciences access to Eli Lilly's drug discovery and development capabilities, as well as its global commercialization infrastructure.
The company's pipeline includes several AOC-based drug candidates in various stages of development. Some of the key programs include treatments for myotonic dystrophy type 1, muscle wasting disorders, and cancer. These drug candidates are designed to target specific disease-causing proteins and modulate their expression or activity using oligonucleotide-based therapies.
Avidity Biosciences also focuses on optimizing the delivery of AOCs to ensure effective delivery into target cells and tissues. The company utilizes its expertise in chemistry, biology, and pharmacology to design optimized conjugation strategies, develop novel delivery systems, and enhance drug stability and pharmacokinetics.
In addition to its drug development efforts, Avidity Biosciences is actively involved in intellectual property protection and has a robust patent portfolio covering its AOC platform technology and specific drug candidates. This provides the company with a competitive advantage and strengthens its position in the biotechnology industry.
Overall, Avidity Biosciences Inc is a pioneering biotechnology company that aims to revolutionize the field of precision medicine through its unique AOC platform technology. With a strong focus on research and development, strategic collaborations, and innovative drug candidates, the company is well-positioned to make significant contributions to the development of novel therapies for various diseases.
Avidity Biosciences seeks to address the limitations of traditional antibody therapeutics by combining the targeting capabilities of antibodies with the precision and versatility of oligonucleotide-based therapies. AOCs are designed to specifically target cells and deliver therapeutic oligonucleotides directly into the cytoplasm of the cells.
The company's platform technology enables the development of novel therapies for a wide range of diseases, including cancer, autoimmune disorders, and rare genetic diseases. AOCs have the potential to target previously undruggable proteins and improve the efficacy and safety of existing therapies.
Avidity Biosciences has a strong focus on research and development to advance its pipeline of AOC-based drug candidates. The company collaborates with various academic institutions, industry partners, and research organizations to leverage their expertise and resources.
One of the notable achievements of Avidity Biosciences is its partnership with Eli Lilly and Company, a global pharmaceutical company. The collaboration aims to discover, develop, and commercialize new AOC-based therapies for immunology and other indications. This collaboration provides Avidity Biosciences access to Eli Lilly's drug discovery and development capabilities, as well as its global commercialization infrastructure.
The company's pipeline includes several AOC-based drug candidates in various stages of development. Some of the key programs include treatments for myotonic dystrophy type 1, muscle wasting disorders, and cancer. These drug candidates are designed to target specific disease-causing proteins and modulate their expression or activity using oligonucleotide-based therapies.
Avidity Biosciences also focuses on optimizing the delivery of AOCs to ensure effective delivery into target cells and tissues. The company utilizes its expertise in chemistry, biology, and pharmacology to design optimized conjugation strategies, develop novel delivery systems, and enhance drug stability and pharmacokinetics.
In addition to its drug development efforts, Avidity Biosciences is actively involved in intellectual property protection and has a robust patent portfolio covering its AOC platform technology and specific drug candidates. This provides the company with a competitive advantage and strengthens its position in the biotechnology industry.
Overall, Avidity Biosciences Inc is a pioneering biotechnology company that aims to revolutionize the field of precision medicine through its unique AOC platform technology. With a strong focus on research and development, strategic collaborations, and innovative drug candidates, the company is well-positioned to make significant contributions to the development of novel therapies for various diseases.
Avidity Biosciences Inc. is a biotechnology company that focuses on developing innovative therapies for a range of diseases, particularly those involving genetic disorders and muscle-related conditions. The companys core technology is based on its proprietary Avidity AWD (Antibody-oligonucleotide conjugate) platform, which combines antibodies and oligonucleotides to create targeted therapies.
Segments
1. Therapeutics Development: This is the primary segment of Aviditys business, where they focus on the research and development of new drugs. Within this segment, the company is dedicated to advancing their lead product candidates through various stages of clinical trials.
2. Research & Development: Avidity invests in R&D to explore new applications of its technology. This segment involves both in-house projects and collaborations with academic institutions and other biotech firms.
3. Manufacturing & Production: Avidity is involved in the production of its therapeutic products, which requires specialized facilities and processes to ensure high-quality manufacturing of biological products, particularly those involving complex conjugation techniques.
Products
1. Lead Product Candidates:
- AOC 1001: This is Aviditys lead program designed for the treatment of muscular dystrophy. It utilizes the companys AOC technology to deliver therapeutic oligonucleotides specifically to muscle tissues, which could potentially address the underlying genetic cause of certain muscular dystrophies.
2. Pipeline Candidates: Avidity Biosciences has a robust pipeline that includes several candidates at various stages of development targeting different diseases. These include:
- Treatments for systemic diseases influenced by muscle tissue and/or other tissues.
- Potential applications in rare diseases, where current treatment options are limited or ineffective.
Services
1. Collaborative Research: Avidity engages in partnerships with academic institutions, research organizations, and other biotech companies for the development of their drug candidates. These collaborations may include joint research initiatives and sharing of technology.
2. Contract Research Organization (CRO) Services: While the primary focus is on internal development, Avidity may engage CROs to assist with various clinical trial phases, including preclinical studies and regulatory submissions.
3. Consultancy: Avidity may provide expertise and consultancy services regarding the development of antisense oligonucleotide therapies and conjugation technologies for other companies or research institutions.
4. Technology Licensing: The company may also explore licensing opportunities for its proprietary technologies, allowing other entities to utilize Aviditys platform for their own therapeutic development.
Target Markets
Avidity focuses on several therapeutic areas, primarily:
- Neurological Disorders: Conditions that can benefit from targeted delivery of genetic therapies.
- Muscle Diseases: Specifically, disorders like Duchenne Muscular Dystrophy (DMD) and other neuromuscular diseases.
- Rare Diseases: Many of Aviditys developments aim to address diseases that are often overlooked by larger pharmaceutical companies due to their small patient populations.
Conclusion
In summary, Avidity Biosciences Inc. is actively engaged in using its novel ADC technology to create targeted therapies for a variety of diseases, particularly those affecting muscle tissues and genetic disorders. Through their lead and pipeline products, collaborative research initiatives, and ongoing commitment to innovation in biotherapeutics, Avidity is positioned to make significant contributions to the biotech field.
Segments
1. Therapeutics Development: This is the primary segment of Aviditys business, where they focus on the research and development of new drugs. Within this segment, the company is dedicated to advancing their lead product candidates through various stages of clinical trials.
2. Research & Development: Avidity invests in R&D to explore new applications of its technology. This segment involves both in-house projects and collaborations with academic institutions and other biotech firms.
3. Manufacturing & Production: Avidity is involved in the production of its therapeutic products, which requires specialized facilities and processes to ensure high-quality manufacturing of biological products, particularly those involving complex conjugation techniques.
Products
1. Lead Product Candidates:
- AOC 1001: This is Aviditys lead program designed for the treatment of muscular dystrophy. It utilizes the companys AOC technology to deliver therapeutic oligonucleotides specifically to muscle tissues, which could potentially address the underlying genetic cause of certain muscular dystrophies.
2. Pipeline Candidates: Avidity Biosciences has a robust pipeline that includes several candidates at various stages of development targeting different diseases. These include:
- Treatments for systemic diseases influenced by muscle tissue and/or other tissues.
- Potential applications in rare diseases, where current treatment options are limited or ineffective.
Services
1. Collaborative Research: Avidity engages in partnerships with academic institutions, research organizations, and other biotech companies for the development of their drug candidates. These collaborations may include joint research initiatives and sharing of technology.
2. Contract Research Organization (CRO) Services: While the primary focus is on internal development, Avidity may engage CROs to assist with various clinical trial phases, including preclinical studies and regulatory submissions.
3. Consultancy: Avidity may provide expertise and consultancy services regarding the development of antisense oligonucleotide therapies and conjugation technologies for other companies or research institutions.
4. Technology Licensing: The company may also explore licensing opportunities for its proprietary technologies, allowing other entities to utilize Aviditys platform for their own therapeutic development.
Target Markets
Avidity focuses on several therapeutic areas, primarily:
- Neurological Disorders: Conditions that can benefit from targeted delivery of genetic therapies.
- Muscle Diseases: Specifically, disorders like Duchenne Muscular Dystrophy (DMD) and other neuromuscular diseases.
- Rare Diseases: Many of Aviditys developments aim to address diseases that are often overlooked by larger pharmaceutical companies due to their small patient populations.
Conclusion
In summary, Avidity Biosciences Inc. is actively engaged in using its novel ADC technology to create targeted therapies for a variety of diseases, particularly those affecting muscle tissues and genetic disorders. Through their lead and pipeline products, collaborative research initiatives, and ongoing commitment to innovation in biotherapeutics, Avidity is positioned to make significant contributions to the biotech field.